Under terms of the agreement, Amgen will pay Ortho Biotech $200 million and the pending litigation in New Jersey District Court will be dismissed with prejudice. Amgen continues to deny that its challenged conduct was unlawful, and admits to no wrongdoing as part of the settlement agreement.
Ortho Biotech, a subsidiary of Johnson & Johnson, had alleged that discounts offered to oncology clinics on Amgen’s Neupogen and Neulasta and Aranesp products violated antitrust laws.
Kevin Sharer, chairman and CEO of Amgen, said: “We are pleased to have reached a settlement that puts this litigation behind us. We believe eliminating the expense and uncertainty of this suit is in the best interest of shareholders.”